Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2018

View Archived Issues

How resistant bacteria lock in their gains

How failing hearts try to save themselves

Efflux pumps protect against more than antibiotics

AsclepiX obtains funds to advance AXT-107

KemPharm adds drug for stimulant use disorder to pipeline

MYK-581 leads to contractile regulation with improved compliance and functional reserve in HCM model

AEG-1 as a promising new therapeutic target in Parkinson's disease

Prior experience and OX2 receptor activation is linked to social stress resilience

Blocking BigLEN-GRP171 signaling reduces opioid addiction and withdrawal in mice

Shifa Biomedical presents data on new PCSK9 inhibitor P-21

MSC-derived EVs contribute to aortic tissue repair and remodeling in aortic aneurysm via miR-147

Obesity is net positive for checkpoint blockers

National University of Singapore and collaborators patent BAD inhibitors

Leidos Biomedical Research and the University of California describe RAS GTPase inhibitors

SSAO inhibitors discovered at Sichuan Kelun-Biotech Biopharmaceutical

U.S. Rare Earth Minerals changes name to Bioxytran

Novan presents preliminary phase II results for SB-206 as treatment of molluscum contagiosum

Redx nominates oral porcupine inhibitor RXC-006 as development compound to treat IPF

Selection Bioscience presents new proteasome inhibitors

Takeda identifies extracellular calcium-sensing receptor antagonists

Five Prime initiates phase I study of first-in-class CD80 fusion protein FPT-155

Researchers present first clinical data for MK-7684

Advanced Proteome Therapeutics reports positive preclinical results with lead ADC

Data presented from a dose-escalation, phase I trial of LY-3200882

GeoVax and Virometix to collaborate on development of HPV vaccine

KEYNOTE-181 shows OS benefit with Keytruda in second-line esophageal cancer

Mission Therapeutics and AbbVie collaborate on DUB inhibitors for Alzheimer's and Parkinson's

European Commission approves Cabometyx for HCC previously treated with sorafenib

Bayer's regorafenib first to enter GBM AGILE platform trial

Interim analysis data presented for phase IIa study of GLS-4/ritonavir combination in chronic HBV

Cadent initiates phase IIa study with CAD-1883 in essential tremor

Alector initiates first-in-human study of AL-002 for Alzheimer's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...